How should organisations validate AI agent baselines before production in healthcare?

Why This Matters for Security Teams

Healthcare agent baselines are not just a lab exercise. A baseline that looks safe in staging can fail the moment it meets production encounter spikes, write-back timing, or clinical workflow coupling. For AI agents with tool access, the real risk is not only data exposure but the agent taking actions outside the intended clinical path. That is why baseline validation must be workload-shaped, not just security-shaped, and why current guidance increasingly points to runtime governance in OWASP Agentic AI Top 10 and the NIST AI Risk Management Framework.

NHI Management Group has also documented how agent misuse becomes visible only after deployment, not during design. In the AI Agents: The New Attack Surface report, 80% of organisations said agents had already performed actions beyond intended scope. In healthcare, that failure mode matters because a harmless-looking test can miss the exact access bursts and write-back patterns that trigger unsafe privilege use. In practice, many security teams discover baseline drift only after a production workflow has already been disrupted, rather than through intentional validation.

How It Works in Practice

Baseline validation for healthcare agents should start by recreating the clinical shape of the workload, not just the syntax of the data. That means synthetic or de-identified traffic should reflect encounter bursts, seasonal load, role-based clustering, and the specific mix of read, summary, and write-back actions the agent will execute. A strong baseline test also checks whether the agent’s identity, credentials, and tool permissions are evaluated at runtime rather than assumed from a static role. For autonomous systems, static IAM often fails because the access pattern is dynamic, goal-driven, and impossible to predict fully in advance.

Practitioners should validate three layers together: workload realism, policy enforcement, and revocation behaviour. Workload realism confirms the staging envelope matches production enough to expose hidden dependencies. Policy enforcement checks whether intent-based decisions, policy-as-code, and least privilege hold under pressure. Revocation behaviour ensures that just-in-time credentials, short-lived tokens, and any approval gates fail closed when the agent strays. That operational pattern is consistent with the direction of the CSA MAESTRO agentic AI threat modeling framework and the MITRE ATLAS adversarial AI threat matrix.

NHI Management Group research shows why this matters in the real world: agent scope creep is common once the model is connected to live systems, as reflected in the OWASP NHI Top 10. A practical validation plan usually includes:

• Replay of representative clinical bursts, not just average throughput.
• Simulation of provider, nurse, and back-office access patterns separately.
• Testing that write-backs happen only when the runtime context justifies them.
• Short-lived credentials that expire cleanly after each task or session.
• Audit traces that prove what the agent saw, decided, and changed.

These controls tend to break down when the staging system is too small, too clean, or too disconnected from the live EHR and integration landscape because the agent never encounters the same tool chain or decision pressure.

Common Variations and Edge Cases

Tighter baseline validation often increases testing cost and delays go-live, requiring organisations to balance clinical safety against delivery speed. The hardest cases are environments with highly variable scheduling, federated data sources, or asynchronous write-back queues, because the agent’s behaviour can look correct in isolation and still become unsafe once timing changes. Current guidance suggests treating those environments as separate baseline classes rather than forcing one universal profile.

There is also no universal standard for this yet on how much de-identified traffic is “close enough.” Some healthcare teams can use de-identified replay safely, while others need synthetic overlays to preserve correlation patterns without exposing patient data. The key is whether the baseline reproduces the decision surface the agent will face, not whether the sample is statistically elegant. That is where the State of Secrets in AppSec research is relevant: security confidence often exceeds actual operational control, and healthcare agent baselines can fail in the same way when assumptions are not pressure-tested.

For implementation teams, the safest rule is simple: if the agent is expected to touch real clinical systems, validate it against production-like tool access, runtime policy evaluation, and revocation events before it is allowed to act. Where the agent depends on stable human-like routines, the baseline often breaks down because real clinical operations are discontinuous, exception-driven, and full of edge-case escalations.

Related resources from NHI Mgmt Group

• When should organisations treat an AI agent as a privileged system?
• How can organisations test AI agent access before production use?
• How should organisations validate browser-agent success before production release?
• What is the difference between human identity governance and AI agent governance?